Eli Lilly and Co
LLY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$375.00 | Whnd | Lfdqypsjdt |
Eli Lilly: Versanis Acquisition Nets New Mid-Stage Weight Loss Drug at a Reasonable Price
Eli Lilly's announced acquisition of the private cardiometabolic firm Versanis Bio for up to $1.925 billion doesn't have a major impact on our Lilly fair value estimate or wide moat rating. However, the acquisition gives Lilly another potential weight-loss treatment with phase 2 drug bimagrumab.